Arrhythmia Clinical Trial
Official title:
Cardiac Rhythm Abnormalities in Patients With Refractory Epilepsy at High Risk for Sudden Death
People with epilepsy are at a higher risk for sudden unexpected death than the general
population. Sudden unexpected death in epilepsy (SUDEP) is a major cause of death in this
population, accounting for 10-50% of deaths for those with epilepsy. The risk for SUDEP is
particularly high for those with refractory epilepsy. Several lines of evidence support a
cardiac mechanism for SUDEP.
This study plans to determine:
1. the frequency and types of cardiac arrhythmias that occur in this population and
2. whether these are increased above the general population in the same age group.
Additionally, these data will be correlated to specific clinical data, including seizure
history, anticonvulsant medications, and any accompanying clinical symptoms.
By employing long-term electrocardiographic monitoring, this study plans to determine:
1. the frequency and types of cardiac arrhythmias that occur in patients with uncontrolled
seizures and
2. whether these are increased above the general population in the same age group.
The specific aims:
1. Identify the types, frequency, and duration of cardiac arrhythmias that occur in
patients with refractory epilepsy and compare these data to available normative data.
2. Correlate abnormal heart rates and rhythms to specific clinical data:
1. seizure type,
2. seizure frequency,
3. probable location of seizure onset in the brain, when such data are available,
4. duration of seizures, and
5. type(s) and number of anticonvulsant medications being used.
3. Correlate cardiac arrhythmias to clinical symptoms
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05048602 -
Drug-induced Brugada Syndrome Research Database
|
||
Completed |
NCT05053243 -
Clinical Validation of the AliveCor Kardia 12L and 6L Devices
|
N/A | |
Completed |
NCT01913561 -
The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection
|
N/A | |
Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
Completed |
NCT01396226 -
A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients
|
Phase 2 | |
Completed |
NCT00756886 -
Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study
|
N/A | |
Terminated |
NCT00624520 -
Mental Stress Reduction in Defibrillator Patients
|
Phase 3 | |
Terminated |
NCT00721149 -
NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study
|
Phase 3 | |
Completed |
NCT00510029 -
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
|
Phase 1 | |
Completed |
NCT00578617 -
Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial
|
N/A | |
Active, not recruiting |
NCT00135174 -
Cost-Effectiveness of Routine Follow-up Visits in Patients With a Pacemaker: The Followpace Study
|
N/A | |
Completed |
NCT00119847 -
Electrophysiological Effects of Late PCI After MI
|
N/A | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT00035490 -
Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators
|
Phase 3 | |
Completed |
NCT00004560 -
Public Access Defibrillation (PAD) Community Trial
|
Phase 3 | |
Completed |
NCT01076361 -
Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study
|
N/A | |
Recruiting |
NCT00138931 -
Genetics of Cardiovascular and Neuromuscular Disease
|
||
Completed |
NCT01076348 -
Model 4965 Post-Approval Study
|
||
Completed |
NCT00622453 -
Arrhythmias in Myotonic Muscular Dystrophy
|
N/A | |
Completed |
NCT00000531 -
Antiarrhythmics Versus Implantable Defibrillators (AVID)
|
Phase 3 |